Week 39 · September 2026
September 2026
A curated, open repository of psychedelic clinical trials, research, and regulatory updates. 1371 entries — updated weekly.
Read this week's full issue →Phase 2 · Ketamine
Symptom-level and network analyses of ketamine treatment in treatment-resistant depression: A pooled analysis of two randomized controlled trials.
We examined symptom-level treatment effects and exploratory symptom networks after ketamine in treatment-resistant depression.…
Sep 26, 2026
Read on PubMed →
Featured This Week
PubMed · Sep 25, 2026
Ketamine
Phase 2
Tobacco use remains a leading preventable cause of morbidity and mortality. Although several pharmacotherapies and behavioral treatments for tobacco use disorder (TUD) exist, their overall efficacy is modest, underscoring the need for innovative treatment approaches.…
Chacruna Institute · Sep 23, 2026
Other
News
This article discusses the importance of psychedelic harm reduction and introduces experts in the field, including Tomislav Majic, Maha N. Mian, and Helena Aicher, who are involved in research and clinical practice related to psychedelic substances and their risks.
PubMed · Sep 21, 2026
Psilocybin
Phase 2
Individuals with bipolar II disorder (BD-II) and depression face limited treatment options and are often excluded from psilocybin therapy trials due to concerns about precipitating mania or psychosis.…
More from the Feed
Ketamine